Heartworm Disease in Dogs — Comprehensive Management Guide

Complete, practical guide to canine heartworm: lifecycle, testing schedule, prevention, melarsomine-based treatment with doxycycline, complications, and the slow‑kill controversy.

Quick Overview

• What it is: Heartworm disease in dogs (caused by Dirofilaria immitis) is a mosquito-transmitted parasitic infection that lives in the pulmonary arteries and right heart, causing progressive cardiopulmonary disease.
• Who’s at risk: Any dog in mosquito habitats — risk is highest in endemic regions (Gulf Coast, Mississippi River valley, southeastern U.S., parts of Europe). Outdoor dogs, hunting and working breeds, and unprotected dogs are at greatest risk.
• Prognosis: With prompt, guideline-based adulticidal therapy and strict management, many dogs recover to good quality of life. Severe cases (caval syndrome, advanced pulmonary hypertension) carry higher morbidity and mortality.

Pathophysiology (explained simply)

• Lifecycle: An infected mosquito deposits infective larvae (L3) into the dog during feeding. Larvae mature to adults over ~6–7 months. Adult worms (male and female) reside in pulmonary arteries and right heart, where females release microfilariae into the bloodstream.
• Damage: Adult worms cause inflammation of pulmonary arteries, vascular remodeling, pulmonary hypertension, and right-sided heart strain. When adults die (spontaneously or from therapy), fragments can embolize to pulmonary vessels causing thromboembolism and acute inflammation.
• Wolbachia: Heartworms carry symbiotic bacteria (Wolbachia) that contribute to inflammation; killing Wolbachia with doxycycline reduces complications.

• No breed is immune; however, certain populations have historically shown higher prevalence: greyhounds (racing/retired), hunting dogs, strays, and dogs in endemic geographic regions.
• Indoor dogs are not risk-free — mosquitoes enter homes. Prevalence tracks with local mosquito and reservoir (untreated stray/feral dog) populations.

A commonly used clinical staging aligns with disease severity:

• Class I (mild): Often asymptomatic or intermittent cough; mild radiographic changes.
• Class II (moderate): Chronic cough, exercise intolerance, mild to moderate radiographic/clinical signs.
• Class III (severe): Marked cough, dyspnea, weight loss, signs of right-sided heart failure, radiographic pulmonary changes.
• Class IV (caval syndrome): Acute collapse, severe hemoglobinuria, jaundice, profound weakness — veterinary emergency requiring immediate intervention.

• Antigen testing: Commercial heartworm antigen tests detect female adult antigens and are the primary screening tool. False negatives can occur in early infection (prepatent period), single-sex male infections, or low worm burden.
• Microfilaria testing: Modified Knott or direct blood smear detects circulating microfilariae; useful for confirming infection, identifying species, and guiding treatment (microfilaricidal therapy).
• Complementary testing: Before adulticidal therapy, perform CBC, serum biochemistry, and urinalysis to evaluate organ function and detect comorbidities. Baseline bloodwork is essential prior to melarsomine.
• Imaging: Thoracic radiographs often show enlarged pulmonary arteries, right cardiomegaly, and interstitial/bronchial patterns. Echocardiography can visualize worms in the pulmonary artery or right heart and assess pulmonary hypertension. Refer to a cardiology/internal medicine specialist for complex or refractory cases, suspected severe pulmonary hypertension, or preoperative planning for caval syndrome.
• Testing schedule (practical):

Treatment options — medical, surgical, and adjuncts

Principles: Adulticide therapy (to kill mature worms), doxycycline to target Wolbachia, macrocyclic-lactone (ML) preventive to remove microfilariae and prevent reinfection, and strict exercise restriction to reduce thromboembolic risk.

1) First-line adulticidal therapy — melarsomine (Immiticide)

• Drug and dosing: Melarsomine dihydrochloride, given intramuscularly into the lumbar epaxial muscles at 2.5 mg/kg per injection.
• Recommended regimen (preferred): 3-dose protocol — a single 2.5 mg/kg injection followed 4 weeks later by two 2.5 mg/kg injections given 24 hours apart. This 3-dose protocol has become the standard due to improved efficacy and fewer complications compared to the older two-injection regimen.
• Hospitalization: Usually outpatient, but severe or unstable patients may require hospitalization for supportive care.

• Rationale: Doxycycline reduces Wolbachia load, diminishes pulmonary inflammation, and improves outcomes when given before melarsomine.
• Dose: 10 mg/kg orally twice daily for 28 days (some clinicians use 5–10 mg/kg BID). Start as soon as diagnosis is confirmed and ideally finish doxycycline prior to adulticide therapy.

• Use monthly MLs both as prevention and to clear microfilariae. They should be started after diagnosis (timing relative to doxycycline and melarsomine varies — clinician-dependent) but are an essential component.
• Common drugs/doses: ivermectin 6 mcg/kg PO monthly (Heartgard), milbemycin oxime 0.5 mg/kg PO monthly (Interceptor), topical moxidectin (2.5 mg/kg) or selamectin 6 mg/kg monthly.

• Exercise restriction: Strict confinement and leash-only walks from diagnosis until at least 4–8 weeks after the last melarsomine injection (many clinicians recommend longer in dogs with severe disease). Exercise restriction reduces the risk of pulmonary thromboembolism.
• Corticosteroids: Prednisone may be used short-term for significant pulmonary inflammation or to treat thromboembolic complications (typical dosing 0.5–1 mg/kg/day tapered per clinical response), but use is individualized.
• Hospitalize and provide oxygen, IV fluids, transfusion support if needed in severe cases or caval syndrome.

• Caval syndrome (Class IV) with severe hemolysis and cardiogenic compromise is an emergency. Surgical removal of worms via jugular venotomy or interventional extraction is often lifesaving but requires specialized centers and carries procedural risk.

• Pulmonary thromboembolism from dying worms — the most common serious complication after adulticide therapy. Clinical signs include sudden worsening cough, respiratory distress, weakness.
• Pulmonary hypertension and right-sided heart failure in chronic disease.
• Anemia, pigmenturia, hemoglobinuria and shock in caval syndrome.
• Renal and hepatic effects — baseline chemistries before therapy mitigate risk.

• Fast-kill (recommended): Melarsomine-based adulticidal therapy combined with doxycycline and MLs. Rapid adulticidal therapy minimizes long-term pulmonary damage and resolves infection relatively quickly. This is the American Heartworm Society (AHS) recommended approach in most dogs.
• Slow-kill (contested): Long-term monthly MLs (often with doxycycline) without melarsomine to gradually kill adults over many months to years. Advantages: lower immediate cost, avoids melarsomine in dogs with severe comorbidities or where melarsomine is unavailable.
• Main concerns with slow-kill:

• Clinical position: Slow-kill is generally not recommended as first-line except in rare circumstances (owner finances, melarsomine contraindications, drug availability) and after informed consent and strict follow-up. If chosen, include doxycycline and continuous ML, and perform frequent rechecks (antigen/microfilaria) until clearance.

• Confirm cure: Antigen testing at 6 and 12 months after the last melarsomine injection; microfilaria testing may be used to confirm clearance earlier.
• Yearly monitoring: Annual heartworm antigen testing for all dogs on prevention remains standard.
• Recheck imaging: Repeat thoracic radiographs and echocardiography for dogs with moderate/severe baseline disease to assess residual pulmonary hypertension and heart remodeling.
• Lifelong prevention: Place all dogs on year-round heartworm preventive after recovery to prevent reinfection.

• Many dogs treated with the recommended melarsomine/Doxy/ML protocol recover excellent quality of life, especially when treated before advanced pulmonary hypertension or right-sided heart failure develop.
• Dogs with severe chronic changes (pulmonary hypertension, extensive vascular remodeling) may have ongoing exercise intolerance or require long-term medical management.
• Caval syndrome has a guarded prognosis even with prompt intervention; however, dogs that survive surgical extraction can recover well.

• Strictly follow exercise restriction rules from your vet; even short bursts of running can precipitate thromboembolism.
• Give doxycycline and preventive medications exactly as prescribed. Missing doses delays recovery and increases risk.
• Keep follow-up appointments for bloodwork and antigen testing at 6 and 12 months after therapy.
• Keep all dogs in the household on year-round prevention; treat/monitor any at-risk new dogs.
• Reduce mosquito exposure where possible (screens, avoiding peak mosquito times, removing standing water), though prevention with medication remains primary defense.

Seek immediate veterinary care if your dog has any of the following:

• Sudden collapse, severe weakness, fainting (syncope)
• Difficulty breathing, cyanotic or blue-tinged gums, or severe rapid breathing
• Dark or red urine, jaundice, or sudden anemia symptoms
• Sudden worsening of cough or exercise intolerance, especially after starting adulticide therapy
• Signs of severe adverse drug reaction (vomiting, severe diarrhea, neurologic signs)

• Heartworm is a preventable but potentially life-threatening disease. Annual testing and year-round prevention are the most effective public health measures.
• The evidence-supported standard of care for most infected dogs is doxycycline plus a monthly ML and a melarsomine adulticide regimen (3-dose protocol), with strict exercise restriction and monitoring.
• Slow-kill protocols carry important downsides and should be used only when melarsomine is contraindicated or unavailable.

Primary citation

American Heartworm Society. Guidelines for the diagnosis, prevention, and management of heartworm (Dirofilaria immitis) infection in dogs. (2018 guideline update). https://www.heartwormsociety.org/resources/american-heartworm-society-guidelines

Additional references

• ACVIM Consensus Statement on Heartworm Disease (2014). Journal of Veterinary Internal Medicine.
• McCall JW, Genchi C, Kramer L, Guerrero J, Venco L. Heartworm disease in animals and humans. Adv Parasitol. 2008;66:193-285.

Frequently Asked Questions